Jeffrey Aronin is passionate about improving the life of his patients. His knowledge of bioscience and medicine can be used to help people in new and innovative ways. He uses that, and his appetite for understanding a patient’s needs, to fuel his hunger to come up with treatments that will make his patient’s lives better. Besides starting his own business and being the CEO of Paragon Biosciences, Jeffrey Aronin has been an integral part of the approval and development of thirteen different medicines, a feat not reached by many.
Jeffrey Aronin is also the recipient of the 2017 Weizmann Award. This award is given to those in the healthcare community who have dedicated their research to helping others have a better life.
Through creative expertise in biotechnology, Jeffrey Aronin has assisted other biotech companies in helping patients who have unmet needs. The first step in making patient’s lives better is to determine which diseases have insufficient treatment plans that need to be addressed. Next, they can focus on the cause of the disease and what steps have not been taken yet. Then, the team decides which type of science they can use to improve the treatment. Finally, Jeffrey Aronin and his team establish companies that are focused on conducting clinical studies that will eventually make way to the regulation and increased knowledge of the new treatment. By doing this, Jeffrey Aronin and his team make treatment more accessible for patients.
Besides this ground-breaking method of bringing new medicines to the market, Jeffrey Aronin is also the founder of MATTER, a Chicago-based company that has facilitated the start of more than 200 companies who will be the future innovators in healthcare.
The Aronin Family Foundation is another way that Jeffrey Aronin puts the patient-first. This foundation supports patient rights and research for rare diseases that sometimes go unnoticed.